Zoetis (ZTS) Issues FY18 Earnings Guidance

Zoetis (NYSE:ZTS) issued an update on its FY18 earnings guidance on Thursday morning. The company provided EPS guidance of $2.96-3.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.98. The company issued revenue guidance of $5.675-5.8 billion, compared to the consensus revenue estimate of $5.62 billion.

Shares of Zoetis (NYSE:ZTS) opened at $76.79 on Thursday. Zoetis has a 52 week low of $52.00 and a 52 week high of $80.13. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $35,688.99, a P/E ratio of 39.19, a PEG ratio of 1.62 and a beta of 1.07.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. Zoetis’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.47 earnings per share. research analysts forecast that Zoetis will post 2.36 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be given a $0.126 dividend. This represents a $0.50 annualized dividend and a yield of 0.66%. The ex-dividend date is Thursday, April 19th. Zoetis’s payout ratio is 26.32%.

Several research analysts have issued reports on ZTS shares. Cowen set a $80.00 price objective on Zoetis and gave the stock a buy rating in a research report on Friday, November 17th. Jefferies Group reiterated a buy rating on shares of Zoetis in a research report on Friday, November 10th. BidaskClub upgraded Zoetis from a hold rating to a buy rating in a research report on Tuesday, November 7th. Cantor Fitzgerald reiterated a buy rating and issued a $75.00 price objective on shares of Zoetis in a research report on Tuesday, October 24th. Finally, Stifel Nicolaus reiterated a buy rating and issued a $65.00 price objective on shares of Zoetis in a research report on Tuesday, October 24th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $73.72.

TRADEMARK VIOLATION WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/15/zoetis-zts-issues-fy18-earnings-guidance.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply